Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (TSE:FRX)
:FRX
RESEARCH TOOLSreports
FRX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$5.65 - C$17.00
Previous CloseN/A
Volume1.30K
Average Volume (3M)654.00
Market Cap
C$262.48M
Enterprise ValueC$169.42M
Total Cash (Recent Filing)$13.65M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding27,427,704
10 Day Avg. Volume936
30 Day Avg. Volume654
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)-20.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.47
Enterprise Value/Ebitda47.05
Forecast
1Y Price Target
C$19.99Price Target Upside111.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Fennec Pharmaceuticals News
PremiumCompany Announcements
Fennec Pharmaceuticals Reports Strong Growth Amid Challenges
PremiumCompany Announcements
Fennec Pharmaceuticals Reports Strong 2024 Sales Growth
---
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyPEDMARK has unique IP protection until 2039 and orphan drug status until 2029, providing a competitive advantage.
Market ExpansionFennec Pharmaceuticals is poised to benefit from market expansion to the adolescent and young adult (AYA) community, with notable adoption within prominent academic centers like Cedars-Sinai and Mount Sinai.
Reimbursement SuccessFennec surpassed 90% reimbursement in the AYA population for PEDMARK, indicating a strong position in this significant market segment.
Bears Say
Financial PerformanceFennec Pharmaceuticals' 3Q24 financial results missed revenue and bottom-line forecasts, indicating challenges in meeting financial expectations.
Revenue DeclineFennec recorded product revenue totaling only $7M, which represented a modest quarter-over-quarter decline compared to 2Q24.
Revenue ProjectionsThe full-year 2025 total revenue estimate has been modestly reduced to $46.7M from the prior estimate of $48.4M.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.70% Insiders
5.12%
Mutual Funds
― Other Institutional Investors
86.59% Public Companies and
Individual Investors
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$5.65 and its highest was C$17.00 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is C$262.48M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Mar 10, 2025. The company reported -C$0.087 earnings per share for the quarter, beating the consensus estimate of -C$0.185 by C$0.098.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is -0.13.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 27,427,704 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -C$0.087 in its last earnings report, beating expectations of -C$0.185. Following the earnings report the stock price went down -10.285%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
---
Fennec Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$19.99 (111.26% Upside)
C$19.99 (111.26% Upside)
Blogger Sentiment
Bullish
TSE:FRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $46.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.88%
12-Months-Change
Fundamentals
Return on Equity
21.91%
Trailing 12-Months
Asset Growth
67.31%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. (FRX) is a biopharmaceutical company focused on the development and commercialization of innovative treatments for cancer patients. The company is primarily known for its efforts in developing PEDMARK™, a formulation aimed at preventing ototoxicity, or hearing loss, in pediatric patients undergoing chemotherapy with cisplatin, a widely used chemotherapy drug. Fennec Pharmaceuticals operates within the pharmaceutical sector, with an emphasis on oncology and pediatric care.
---
FRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, successful international launches, and strong financial management. However, increased operating expenses and challenges in awareness and adoption of PEDMARK, particularly in the AYA segment, were noted.Read More>---
FRX Stock 12 Month Forecast
Average Price Target
C$19.99
▲(111.26% Upside)
Technical Analysis
Best Analysts Covering FRX
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
-3.56%
reiterated a buy rating 16 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of -3.56% per trade.
---